Posterior Cervical: The Segment Everyone Serves and Nobody Owns

Seventy systems, reimbursement falling around nine percent a year, and a patient population that keeps getting older.

Posterior cervical fixation wins the demographic argument in spine and still gets treated as a checkbox. It sits behind lumbar interbody in most portfolio reviews, behind whatever the enabling-technology line item is that quarter, and the commercial teams that do sit down with it are usually working from market numbers that are wrong by a factor of four or five. So it’s worth going slowly through what the data actually supports.

The age split is the place to start. In a sixteen-year New York state series of 87,045 subaxial cervical fusions, anterior approaches accounted for 85.2% of cases against 12.3% posterior and 2.5% circumferential, with mean patient age of 49.8 years anteriorly and 59.9 posteriorly. Ten years of difference between the two populations, and that gap explains most of what follows. Anterior surgery gets the working-age radiculopathy patient; posterior gets the older one with multilevel disease and cord compression, which is the cohort demographics keep manufacturing.

Projections built from national inpatient data put posterior cervical decompression and fusion up 19.3% between 2020 and 2040, roughly 29,600 cases to 35,300, against 13.3% growth for ACDF over the same period — off a much smaller base, obviously, but in the right direction. The historical divergence was steeper still. Looking specifically at cervical spondylotic myelopathy, one national series found PCF volumes rose 291% between 2003 and 2013.

The anterior side, meanwhile, is being squeezed from two sides at once. ACDF is still the most commonly performed cervical procedure in the United States, but its frequency has begun to fall. Arthroplasty is quietly taking the young single-level patient off the top: disc replacement went from 4.0% of cervical procedures in 2010 to 14.1% in 2018 and 14.4% by 2021. Nobody is developing a motion-preserving alternative for the sixty-eight-year-old with four-level stenosis, so that patient will keep receiving screws and rods for the foreseeable future.

That’s the structural case, and it’s solid. The financial case is a different conversation.

Inflation-adjusted reimbursement across cervical procedures has been falling at roughly 9% a year, which compounds into something serious over a decade. It’s the classic setup for margin pressure: volumes flat to rising, payment eroding, and hospitals responding by squeezing implant contracts and hardening value-analysis committees against anything that can’t show a cost argument. Differentiated screw geometry does not survive that conversation well.

The ASC narrative is messier than the pitch decks allow. Single-level PCDF in hospital-owned ambulatory surgery centers grew from 577 cases in 2016 to 3,307 in 2021, then dropped back to 1,586 in 2022, while median inflation-adjusted charges climbed from about $41,700 to $69,300. That isn’t a ramp, it’s a spike followed by a retreat, and the retreat is probably the correct clinical answer given the complication profile of posterior cervical work. Lumbar migrated outpatient; cervical posterior has not, and building a tray specifically around ASC economics is building for a channel that hasn’t yet demonstrated it wants the procedure.

Market sizes that don’t reconcile

Our own product library currently tracks seventy-three posterior cervical systems, a handful of which appear to have quietly disappeared. That is a lot of screw-and-rod sets for one procedure family.

Chasing how much revenue, exactly, is where the published research becomes useless. Cervical fixation overall, anterior and posterior together, has been sized globally at just over $1.9 billion for 2024, growing around 4.1%. Syndicated reports that try to isolate posterior cervical alone have come in anywhere between $1.2 billion and $2.0 billion globally. Set against that, the U.S. opportunity was pitched at more than $250 million at the NorthStar OCT launch, and our own earlier coverage of the segment used $350 million.

Both families of numbers cannot be right. A U.S. market of $250–350M does not fit inside a global posterior-only market of $2B when North America dominates spine hardware consumption the way it does. Our working estimate, and we’d label it as an estimate rather than a finding, is that posterior cervical hardware in the U.S. runs somewhere between $300M and $500M, and that the billion-dollar figures are quietly bundling anterior plates, cages, or the whole cervicothoracic construct. If your business case rests on the larger numbers, it rests on a category definition rather than on a market.

Which means: seventy-three systems, maybe four hundred million dollars, and a median system generating single-digit millions.

Who’s left, and who left

Look past the top tier and the fragmentation isn’t only between companies. It’s inside them. Globus carries Quartex and Ellipse alongside Reline Cervical, inherited from the NuVasive side — and its international catalogue lists further posterior cervical products beyond those. Medtronic runs Vertex and Infinity. DePuy Synthes went furthest the other way, collapsing Synapse and Mountaineer into Symphony. VB Spine has Yukon, with Oasys lingering as a registration ghost — gone from the website, still labelled in the FDA’s database to a company that sold the business sixteen months ago.

Highridge fields Virage, Orthofix has NorthStar out of SeaSpine, and Spinal Elements has just launched Overwatch PCF above its own Lotus line, which is the same duplication starting again in real time. Seven organisations, and beneath them the sixty-odd systems listed at the end of this piece — stripped of branding, a top-loading polyaxial screw, a 3.5mm rod, an occipital plate, a handful of connectors, and an angulation figure quoted in whichever convention flatters it. So the interesting question isn’t why so many companies compete here. It’s why a company that already sells the newer system keeps the older one on the price list. Revision obligations explain part of it and international registrations another part. What explains the rest is that discontinuing a tray means telling a surgeon who has used it for ten years that it’s gone, and no commercial organisation has ever decided that conversation is worth having.

Real differentiation has narrowed to four things: angulation, the cervicothoracic transition, occipital plate design, and navigation compatibility. The angulation claims deserve the most scepticism, because there’s no shared convention. Virage’s omnidirectional screw is quoted at 56° of angulation and 112° of conical range — same screw, two headline numbers. Spinal Elements advertises 120° on Overwatch PCF. Nobody normalizes these before building comparison slides, and the trade-off rarely gets mentioned: Globus says plainly in its own materials that increased angulation and dual-rod-capable tulips come at the cost of bulkier screws.

Navigation is where the segment actually divides. Mid-caps can’t fund robotics programmes, so they build to StealthStation and NavLock and rent the installed base. Costs nothing in capital, works well enough. It also means competing on Medtronic’s screens, in Medtronic’s ecosystem, against Medtronic’s own posterior cervical portfolio. That’s the bargain on offer in 2026, and below the top tier there isn’t an obvious alternative.

Three things worth watching. Laminoplasty as a motion-preserving competitor remains marginal — in a 2015–2023 series of 77,514 posterior cervical cases, laminoplasty accounted for 5,581 against 71,933 fusions — but it’s the only real alternative anyone is developing. Osteoporosis in an aging PCF population is the more interesting gap, since cement augmentation and fenestrated fixation have barely arrived in the cervical spine. And consolidation, which with a list this long and falling reimbursement is arithmetically inevitable. Stryker just took the fastest route to it.

A caveat on the volume figures: they come from inpatient, claims and state-level databases that code these procedures differently, so counts are directionally useful but not comparable study to study.

The systems

What follows is every posterior cervical system we track. Threaded through it are the ones that stopped: Mesa Mini went quiet after Stryker absorbed K2M, PASS OCT disappeared once Medtronic acquired Medicrea, Solanas sat with Alphatec, Nex-Link was Zimmer legacy metal. None failed clinically. They were retired because somebody bought the company that owned them and already sold the same thing. Oasys is next, and Lotus will likely follow. Nobody will announce either, which is why a list like this always runs longer than the market it describes.

###

Legal Disclaimer:

Content published on SPINEMarketGroup (thespinemarketgroup.com) is provided for informational purposes only and on an “as is” basis, without warranties of any kind. We do not guarantee the accuracy, completeness, legality, or reliability of any information, images, videos, links, or third-party materials featured on the site. Any views or claims expressed in contributed content or press releases belong to their respective authors or sources. For copyright concerns, factual corrections, or content-related complaints, please contact us directly for review.

Posterior Cervical: The Segment Everyone Serves and Nobody Owns

Related Posts:

Contact us:

PRIVACY POLICY

Related Posts:

Footer

Contact us:

PRIVACY POLICY